Biologix Hair Inc.
OTCBB : BLGX
OTCQB : BLGX

Biologix Hair Inc.

May 31, 2013 09:15 ET

Biologix Hair Inc. Announces Retention of Ottawa-based Launch IR to Direct Investor Relations Activity

TORONTO, ONTARIO--(Marketwired - May 31, 2013) - Biologix Hair Inc. (OTCBB:BLGX)(OTCQB:BLGX) announces that effective June 1, 2013 Ottawa-based Launch IR has been retained to manage investor relations activities for Biologix, in coordination with the Company's Corporate Communications division.

Launch IR is an experienced consulting/investor relations firm with connections and strong ties to industry leading investment firms in the United States, Europe and Canada, which works with select groups of exceptional public companies, collaborating with management to secure premium valuations.

Matt Harrington, President and Investor Relations Consultant of Launch IR, has 25 years of consulting and marketing experience and building information technology and professional services companies. Mr. Harrington has recently been involved in all aspects of corporate development and investor relations with emerging public companies. Clinton Joseph, Partner and Investor Relations Consultant of Launch IR, also has a technology background with 15 years of professional experience including 10 years experience involving Investor Relations and money raising activities. Mr. Harrington and Mr. Joseph have been involved in numerous investor relations company files together.

Matt Harrington stated: "Biologix Hair Inc. has an exciting breakthrough biopharma product with a truly global market potential, strong leadership with the necessary skill sets and experience to lead the Company and relationships in place with legal and financial advisors to guide the NYSE Market listing application and FDA approval processes. Launch IR has and continues to work with NYSE listed companies and specialize in aligning their institutional relationships with fast growing companies with exceptional potential for long-term growth. Biologix Hair Inc. has created a very promising investment opportunity and we look forward to assisting with coordinating this IR effort."

Biologix Hair Inc. has closed its Corporate Communications office in Halifax, Nova Scotia.

About Biologix Hair Inc. and Biologix Hair Science Ltd.

Biologix Hair Inc. (Biologix Hair), together with its wholly owned biotechnology subsidiary, Biologix Hair Science Ltd. ™ (BHS), is focused on realizing the full market potential for its patent-pending hair loss prevention and regeneration treatment - the Biologix Hair Therapy System™ - and its demonstrated ability to prevent and reverse the effects of alopecia, which plagues hundreds of millions worldwide.

Between mid-2004 and mid-2012, more than 30,000 pre-clinical-trial treatments of Biologix Revive - the essence of the Biologix Hair Therapy System™ - were administered to 5,000-plus patients in South America suffering with varying degrees of alopecia, as well as people seeking preventive treatment. The participating treatment clinicians subjectively observed and reported that virtually 100% of preventive care clients continued to retain their healthy hair and an estimated 80-85% of the males and 90-plus% of the females treated for hair regeneration experienced significant regrowth of their own natural hair. And among alopecia areata patients, virtually total hair regrowth was observed in 100% of the cases. To date, no negative side effects have been reported.

BHS is currently focused on obtaining FDA approval for its breakthrough hair loss prevention and regeneration therapy and has initiated a research and development program with one of the world's leading medical research universities, the Beijing Institute of Technology (BIT). The R&D program, expected to take approximately twelve months to complete, is an important final step before formal clinical trials and the FDA approval process begins.

Additionally, on May 11, 2012, Venable LLP, the Washington-based law firm overseeing the worldwide IP and regulatory approval processes on behalf of BHS, filed a Patent Cooperation Treaty (PCT) application on behalf of BHS for Biologix Revive in Geneva, Switzerland. The PCT is an international treaty, administered by the World Intellectual Property Organization (WIPO), to which 147 countries have as of now contracted, including Canada and the United States.

Biologix management is determined to be in a ready position to capitalize on the high-margin sales potential of the Biologix Hair Therapy System™, if and when FDA and other major market approvals are forthcoming.

As BHS advances the regulatory approval process, Biologix Hair, together with wholly owned subsidiary companies operated by BHS, are rapidly developing a global distribution network of licensed clinicians and medical practitioners seeking to become Certified Biologix Hair Therapists™ and secure exclusive territorial purchasing and treatment rights for the Biologix Hair Therapy System™.

Biologix Hair has decided not to risk creating any potential regulatory conflicts by offering treatment outside the United States and other major high-product-margin markets until FDA approval has been granted. Therefore, the Biologix Hair Therapy System™ is not yet available other than to the 5,000+ patients who participated in the pre-clinical-trials conducted in South America.

To learn more about Clinician Licensing opportunities, Click Here or call toll free +1 855.737.0333 or +1 647.344.5900.

Disclaimer

This announcement is not an offer to sell any Biologix Hair Inc. ("Biologix") securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of Biologix may contain "forward-looking statements". Such forward-looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and includes, without limitation, the development of treatment centers and approval from regulatory authorities as well as the ability for Biologix to obtain adequate financing to meet its business objectives. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors beyond our control that could cause actual events or results to be significantly different from those described in the forward-looking statements. Any or all of our forward-looking statements in this report or in any other public statements we make may turn out to be wrong. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise. In Canada, Europe and the United States, the Biologix treatment is not approved for use by Health Canada, EMA or the FDA. The company makes no representations that it will receive Health Canada, EMA or FDA approvals.

Contact Information